Pleiotropic Effects of Apolipoprotein E in Dementia: Influence on Functional Genomics and Pharmacogenetics

  • Ramón Cacabelos
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Cholinesterase Inhibitor Poor Metabolizers Extensive Metabolizers ApoE Genotype CYP2D6 Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cacabelos R. Molecular genetics of Alzheimer's disease and aging. Genomic Medicine Series. Part 1. Methods Find Exp Clin Pharmacol 200527(suppl A):1–573.Google Scholar
  2. Cacabelos R, Fernández-Novoa L, Corzo L, et al. Phenotypic profiles and functional genomics in dementia with a vascular component. Neurol Res 2004;26:459–480.PubMedCrossRefGoogle Scholar
  3. Cacabelos R, Fernández-Novoa L, Corzo L, et al. Genomics and phenotypic profiles in dementia: implications for pharmacological treatment. Methods Find Exp Clin Pharmacol 2004;26(6):421–444.PubMedGoogle Scholar
  4. Teter B, Finch CE. Caliban's heritance and the genetics of neuronal aging. Trends Neurosci 2004;27(10):627–632.PubMedCrossRefGoogle Scholar
  5. Wright AD, Jaconson SG, Cideciyan AV, et al. Lifespan and mitochondrial control of neurodegeneration. Nat Genet 2004;36:1153–1158.PubMedCrossRefGoogle Scholar
  6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(suppl):245–254.PubMedCrossRefGoogle Scholar
  7. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005;6:287–298.PubMedCrossRefGoogle Scholar
  8. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002;3:67–99.PubMedCrossRefGoogle Scholar
  9. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545–584.PubMedCrossRefGoogle Scholar
  10. Roses AD, Pangalos MN. Drug development and Alzheimer's disease. Am J Geriatr Psychiatry 2003;11:123–130.PubMedCrossRefGoogle Scholar
  11. Cacabelos R, Alvarez XA, Lombardi V, et al Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000;6:415–499.Google Scholar
  12. Suh YH, Checler F. Amyloid precursor protein, presenilins, and a-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Phamacol Rev 2002;54:469–525.Google Scholar
  13. Cacabelos R, Lombardi V, Fernández-Novoa L, et al. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Takeda M, Tanaka T, Cacabelos R (eds) Molecular Neurobiology of Alzheimer Disease and Related Disorders. Basel: Karger, 2004, pp 236–285.CrossRefGoogle Scholar
  14. Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 2003;4(5):597–621.PubMedCrossRefGoogle Scholar
  15. Cacabelos R. Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics 2004;5(8):1049–1105.PubMedCrossRefGoogle Scholar
  16. Cacabelos R, Fernández-Novoa L, Pichel V, et al. Pharmacogenomic studies with a combination therapy in Alzheimer's disease. In: Takeda M, Tanaka T, Cacabelos R (eds) Molecular Neurobiology of Alzheimer Disease and Related Disorders. Basel: Karger, 2004, pp 94–107.CrossRefGoogle Scholar
  17. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 2003;25:567–580.PubMedCrossRefGoogle Scholar
  18. Cacauelos R. Pharmacogenomics and Nutrigenomics. Scientific Progress and Pharmaceutical Development. Coruña: Ebiotec Foundation, 2004.Google Scholar
  19. Kalow W, Grant DM. Pharmacogenetics. In: Scriver CR, Beaudet AL, Sly WS, et al (eds) The Metabolic Š Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001, pp 225–255.Google Scholar
  20. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529–537.PubMedCrossRefGoogle Scholar
  21. Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538–549.PubMedCrossRefGoogle Scholar
  22. Nebert DW, Jorge-Nebert LF. Pharmacogenetics and pharmacogenomics. In: Rimoin DL, Connor JM, Pyeritz R, Korf BR (eds) Emery and Rimoin's Principles and Practice of Medical Genetics, 4th ed. Edinburgh: Churchill-Livingstone, 2002, pp 590–631.Google Scholar
  23. Tribut O, Lessard Y, Reymann JM, et al. Pharmacogenomics. Med Sci Monit 2002;8:152–163.Google Scholar
  24. Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 2000;22:695–705.PubMedCrossRefGoogle Scholar
  25. Saito S, Ishida A, Sekine A, et al. Catalog of 680 variants among eight cytochrome P450 (CYP) genes: nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003;48:249–270.PubMedCrossRefGoogle Scholar
  26. Wooding SP, Watkins SW, Bamshad MJ, et al. DNA sequence variations in a 3.7-kb noncoding sequence 5-prime of the CYP1A2 gene: implications for human population history and natural selection. Am J Hum Genet 2002;71:528–542.PubMedCrossRefGoogle Scholar
  27. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815–850.PubMedCrossRefGoogle Scholar
  28. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Exp Opin Pharmacother 2005;6:1967–1987.CrossRefGoogle Scholar
  29. Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 2003;42(15):1383–1392.PubMedCrossRefGoogle Scholar
  30. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41(10):719–739.PubMedCrossRefGoogle Scholar
  31. Cacabelos R, Alvarez A, Fernández-Novoa L, Lombardi VRM. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand 2000;176(suppl):12–19.CrossRefGoogle Scholar
  32. Cacauelos R. Pharmacogenomics in Alzheimer's disease. Mini Rev Med Chem 2002; 2:59–84.CrossRefGoogle Scholar
  33. Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002; 34:357–379.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ramón Cacabelos
    • 1
  1. 1.EuroEspes Biomedical Research CenterInstitute for CNS Disorders15166-BergondoSpain

Personalised recommendations